The current study adds to an increasingly significant body of literature identifying that resistance to AR-targeted therapy may arise, in part, because of inhibiting AR function in the vascular endothelium, as well as within malignant prostate cancer cells. This evidence concerns the gene AR and Familial prostate cancer.